Синдром Хиппеля–Линдау: морфологические аспекты

Ген-супрессор опухолей VHL играет важную роль в регуляции различных клеточных процессов, включая ангиогенез, апоптоз и контроль клеточного цикла. Мутации в этом гене ассоциированы с развитием синдрома Хиппеля–Линдау. Он представляет собой мультисистемное нарушение с выраженной фенотипической изменчивостью, при котором развиваются как доброкачественные, так и злокачественные опухоли различных локализаций. Морфологическая картина опухолей при синдроме Хиппеля–Линдау имеет ряд особенностей, а дифференциальный диагноз может представлять проблему.

1. WHO Classification of Tumours. Genetic Tumour Syndromes. 5th ed. International Agency for Research on Cancer Publications. Lyon, 2024. Available at: https://tumourclassification.iarc.who.int/welcome/

2. Rubin M.A., Aldape K., Perry В. Von Hippel–Lindau syndrome (VHL). In: WHO Classification of Tumours. Genetic Tumour Syndromes. 5th ed. International Agency for Research on Cancer Publications Lyon, 2024. Available at: https://tumourclassification.iarc.who.int/welcome/

3. Collins E.T. Intra-ocular growths (two cases, brother and sister, with peculiar vascular new growth, probably retinal, affecting both eyes). Trans Ophthalmol Soc UK 1894;14(141):141–9.

4. Hippel E., Netzhaut E., Beobachtungen K. Über eine sehr seltene erkrankung der netzhaut. Graefes. Archiv Clin Exp Ophthalmol 1904;(59):83–106. (In Germ.).

5. Von Hippel E. Vorstellung eines patienten mit einem sehr ungewöhnlicher netzhaut beziehungsweise aderhautleiden. Bericht über die 24. Versammlung der Ophthalmologischen Gesellschaft in Heidelberg 1895;24(269). (In Germ.).

6. Lindau A. Studien über Kleinhirncysten. Bau, pathogenese und beziehungen zur angiomatosis retinae. Acta Pathol Microbiol Scand 1926;3(supplement):1–128. (In Germ.).

7. Lindau A. Zur frage der angiomatosis retinae und ihrer hirnkomplikation. Acta Ophthalmol 1927;(4):193–226. (In Germ.).

8. Whaley J.M., Naglich J., Gelbert L. et al. Germ-line mutations in the von Hippel–Lindau tumor-suppressor gene are similar to somatic von Hippel–Lindau aberrations in sporadic renal cell carcinoma. Am J Hum Gen 1994;55(6):1092–102. PMID: 7977367.

9. Melmon K.L., Rosen S.W. Lindau’s disease. Am J Med 1964;36(4):595–617. DOI: 10.1016/0002-9343(64)90107-x

10. Seizinger B.R., Rouleau G.A., Ozelius L.J. et al. Von Hippel– Lindau disease maps to the region of chromosome 3 associated with renal cell carcinoma. Nature 1988;332(6161):268–9. DOI: 10.1038/332268a0

11. Latif F., Tory K., Gnarra J. et al. Identification of the von Hippel–Lindau disease tumor suppressor gene. Science 1993;260(5112):1317–20. DOI: 10.1126/science.8493574

12. Kaelin W.G. Von Hippel–Lindau disease: insights into oxygen sensing, protein degradation, and cancer. J Clin Invest 2022;132(18):e162480. DOI: 10.1172/JCI162480

13. Shirole N.H., Kaelin W.G. Von Hippel–Lindau and hypoxiainducible factor at the Center of Renal Cell Carcinoma Biology. Hematol Oncol Clin North Am 2023;37(5):809–25. DOI: 10.1016/j.hoc.2023.04.011

14. Михайленко Д.С., Горбань Н.А., Залетаев Д.В. Наследственные онкологические синдромы с повышенным риском развития рака почки. Онкоурология 2023;19(3):133–45. DOI: 10.17650/1726-9776-2023-19-3-133-145

15. Gómez-Virgilio L., Velazquez-Paniagua M., Cuazozon-Ferrer L. et al. Genetics, pathophysiology, and current challenges in von Hippel–Lindau disease therapeutics. Diagnostics 2024;14(17):1909. DOI: 10.3390/diagnostics14171909

16. Cicchetti R., Basconi M., Litterio G. et al. Advances in molecular mechanisms of kidney disease: integrating renal tumorigenesis of hereditary cancer syndrome. Int J Mol Sci 2024;25(16):9060. DOI: 10.3390/ijms251690

17. Webster B.R., Gopal N., Ball M.W. Tumorigenesis mechanisms found in hereditary renal cell carcinoma: a review. Genes 2022;13(11):2122. DOI: 10.3390/genes13112122

18. Coco D., Leanza S. Narrative review of von Hippel–Lindau syndrome: from discovery to modern medical and surgical therapies. J Kidney Cancer VHL 2025;12(3):16–24. DOI: 10.15586/jkc.v12i3.396

19. Dogra R., Vaishampayan U. Hypoxia inducible factor-2α (HIF-2α) pathway inhibitors. J Kidney Cancer VHL 2025;12(3):1–15. DOI: 10.15586/jkc.v12i3.413

20. Ohh M., Taber C.C., Ferens F.G., Tarade D. Hypoxia-inducible factor underlies von Hippel–Lindau disease stigmata. Elife 2022;11:e80774. DOI: 10.7554/eLife.80774

21. Lehmann H., Vicari D., Wild P.J., Frew I.J. Combined deletion of Vhl and Kif3a accelerates renal cyst formation. J Am Soc Nephrol 2015;26(11):2778–88. DOI: 10.1681/ASN.2014090875

22. Yanus G.A., Kuligina E.Sh., Imyanitov E.N. Hereditary renal cancer syndromes. Med Sci 2024;12(1):12. DOI: 10.3390/medsci12010012

23. Poulsen M., Budtz‐Jørgensen E., Bisgaard M. Surveillance in von Hippel–Lindau disease (vHL). Clin Genet 2010;77(1):49–59. DOI: 10.1111/j.1399-0004.2009.01281.x

24. Kruizinga R.C., Sluiter W.J., de Vries E.G.E. et al. Calculating optimal surveillance for detection of von Hippel–Lindau-related manifestations. Endocr Relat Cancer 2014;21(1):63–71. DOI: 10.1530/ERC-13-0308

25. Klingler J.H., Gläsker S., Bausch B. et al. Hemangioblastoma and von Hippel–Lindau disease: genetic background, spectrum of disease, and neurosurgical treatment. Childs Nerv Syst 2020;36(10):2537–52. DOI: 10.1007/s00381-020-04712-5

26. Ng H.K., Lazar A.J., Hainfellner J.A., Thway K. Haemangiomas and vascular malformations. In: WHO Classification of Tumours Editorial Board Central nervous system tumours. 5th ed. International Agency for Research on Cancer Publications, 2021. Available at: https://publications.iarc.fr/601

27. Williamson S.R., Zhang S., Eble J.N. et al. Clear cell papillary renal cell carcinoma-like tumors in patients with von Hippel–Lindau disease are unrelated to sporadic clear cell papillary renal cell carcinoma. Am J Surg Pathol 2013;37(8):1131–9. DOI: 10.1097/PAS.0b013e318282dab8

28. Harbi E., Aschner M. Von Hippel–Lindau syndrome: clinical features, genetic foundations, and management strategies. Mol Biol Rep 2025;52(1):281. DOI: 10.1007/s11033-025-10403-8

29. Choueiri T.K., Kaelin W.G. Targeting the HIF2–VEGF axis in renal cell carcinoma. Nat Med 2020;26(10):1519–30. DOI: 10.1038/s41591-020-1093-z

30. Castro-Teles J., Sousa-Pinto B., Rebelo S., Pignatelli D. Pheochromocytomas and paragangliomas in von Hippel–Lindau disease: not a needle in a haystack. Endocr Connect 2021;10(11):R293–304. DOI: 10.1530/EC-21-0294

31. Chittiboina P., Lonser R.R. Von Hippel–Lindau disease. In: Handbook of Clinical Neurology. Elsevier, 2015. Pp. 139–56.

32. Hes F.J., Höppener J.W.M., Lips C.J.M. Pheochromocytoma in von Hippel–Lindau disease. J Clin Endocr Met 2003;88(3): 969–74. DOI: 10.1210/jc.2002-021466

33. Azimi F., Naseripour M., Aghajani A. et al. The genetic differences between types 1 and 2 in von Hippel–Lindau syndrome: comprehensive meta-analysis. BMC Ophthalmol 2024;24(1):343. DOI: 10.1186/s12886-024-03597-1

34. Jung N.Y., Park J.B. Von Hippel–Lindau disease: a comprehensive review of diagnosis, genetics, clinical challenges, and surveillance. J Korean Neurosurg Soc 2025;68(3):338–49. DOI: 10.3340/jkns.2025.0018

35. Cassol C., Mete O. Endocrine manifestations of von Hippel– Lindau disease. Arch Pathol Lab Med 2015;139(2):263–8. DOI: 10.5858/arpa.2013-0520-RS

36. Muller M., Hammel P., Couvelard A. et al. Pancreatic neuroendocrine tumors in french VHL mutation carriers. J Clin Endocrinol Metab 2025;110(4):e1160–6. DOI: 10.1210/clinem/dgae310

37. Rigny M.P., Hammel P., Corcos O. et al. Pancreatic endocrine microadenomatosis in patients with von Hippel–Lindau disease: characterization by VHL/HIF pathway proteins expression. Am J Surg Pathol 2009;33(5):739–48. DOI: 10.1097/PAS.0b013e3181967992

38. Binderup M.L.M., Gimsing S., Kosteljanetz M. et al. Von Hippel– Lindau disease: deafness due to a non-MRI-visible endolymphatic sac tumor despite targeted screening. Int J Audiol 2013;52(11): 771–5. DOI: 10.3109/14992027.2013.824117